ATR and breast neoplasm: Each inhibitor was studied in MCF7 breast tumor cells over a range that included concentrations previously shown to be pharmacologically active (10 μM KU55933 [ATM], 0.4 μM rucaparib [PARP], and 1 μM VE-821 [ATR]) (20–22).